Mirae Asset Global Etfs Holdings Ltd. Moon Lake Immunotherapeutics Transaction History
Mirae Asset Global Etfs Holdings Ltd.
- $47.1 Billion
- Q2 2025
A detailed history of Mirae Asset Global Etfs Holdings Ltd. transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, Mirae Asset Global Etfs Holdings Ltd. holds 15,752 shares of MLTX stock, worth $132,789. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15,752
Previous 13,933
13.06%
Holding current value
$132,789
Previous $544,000
36.58%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding MLTX
# of Institutions
158Shares Held
54.8MCall Options Held
799KPut Options Held
661K-
Bvf Inc San Francisco, CA19.8MShares$167 Million36.63% of portfolio
-
Cormorant Asset Management, LP Boston, MA8.49MShares$71.6 Million40.43% of portfolio
-
Avoro Capital Advisors LLC New York, NY4.15MShares$35 Million3.57% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.61MShares$22 Million0.01% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.67MShares$14.1 Million0.01% of portfolio
About MoonLake Immunotherapeutics
- Ticker MLTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,925,600
- Market Cap $311M
- Description
- MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...